Genetically modified Bifidobacterium displaying Salmonella-antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model
- Authors
- Yamamoto, Sakura; Wada, Jun; Katayama, Takane; Jikimoto, Takumi; Nakamura, Masakuni; Kinoshita, Shohiro; Lee, Kyung-Mi; Kawabata, Masato; Shirakawa, Toshiro
- Issue Date
- 24-Sep-2010
- Publisher
- ELSEVIER SCI LTD
- Keywords
- Bifidobacterium; Mucosal vaccine; Salmonella
- Citation
- VACCINE, v.28, no.41, pp.6684 - 6691
- Indexed
- SCIE
SCOPUS
- Journal Title
- VACCINE
- Volume
- 28
- Number
- 41
- Start Page
- 6684
- End Page
- 6691
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/115661
- DOI
- 10.1016/j.vaccine.2010.08.007
- ISSN
- 0264-410X
- Abstract
- We developed a novel vaccine platform utilizing Bifidobacterium as an antigen delivery vehicle for mucosal immunization. Genetically modified Bifidobacterium longum displaying Salmonella-flagellin on the cell surface was constructed for the oral typhoid vaccine. The efficiency of this vaccine was evaluated in a murine model of typhoid fever. We then orally administered 2.5 x 10(7) CFU of the recombinant Bifidobacterium longum (vaccine) or parental Bifidobacterium longum, or PBS to BALB/C mice every other day for 2 weeks. After the administration, a total of 42 mice (14 mice in each group) were challenged with Salmonella Typhimurium (1.0 x 10(7) CFU/mouse). While 12 mice in the PBS group, and 9 in the parental Bifidobacterium longum group died (median survival: 14 and 25 days), only two in the vaccine group died. These data support that our genetically modified Bifidobacterium antigen delivery system offers a promising vaccine platform for inducing efficient mucosal immunity. (C) 2010 Elsevier Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.